article Open AccessTop 1% cited
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status
Journal of Clinical Oncology · 2011 · Vol. 29(15) · pp. 2011–2019
Eric Van Cutsem✉(National Cancer Institute)Claus-Henning Köhne(National Cancer Institute)István Láng(National Cancer Institute)Gunnar Folprecht(National Cancer Institute)Marek P. Nowacki(National Cancer Institute)Stefano Cascinu(National Cancer Institute)I. Shchepotin(National Cancer Institute)Joan Maurel(National Cancer Institute)David Cunningham(National Cancer Institute)Sabine Tejpar(National Cancer Institute)Michael Schlichting(National Cancer Institute)Angela Zubel(National Cancer Institute)Ilhan Celik(National Cancer Institute)Philippe Rougier(National Cancer Institute)Fortunato Ciardiello(National Cancer Institute)
Abstract
The addition of cetuximab to FOLFIRI as first-line therapy improves survival in patients with KRAS wild-type mCRC. BRAF tumor mutation is an indicator of poor prognosis.
Colorectal Cancer Treatments and StudiesGastric Cancer Management and OutcomesGenetic factors in colorectal cancerCetuximabFOLFIRIKRASMedicineIrinotecanColorectal cancerInternal medicineOncologyHazard ratioFluorouracil
MeSH terms
CetuximabAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCamptothecinLeucovorinFemaleFluorouracilHumansMaleMiddle AgedMutationNeoplasm Metastasis
Citations
1,880
FWCI
90.12
field-weighted impact
References
29
Percentile
100%
vs. same field & year
Citations per year
Cited by
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Oncotarget · 2016 · 325 citations
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
Annals of Oncology · 2012 · 1,518 citations
Drug resistance and new therapies in colorectal cancer
World Journal of Gastroenterology · 2018 · 602 citations
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
The Lancet Oncology · 2014 · 1,720 citations
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
European Journal of Cancer · 2012 · 593 citations
Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances
World Journal of Gastroenterology · 2016 · 412 citations
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Annals of Oncology · 2016 · 3,389 citations
Colorectal cancer: From prevention to personalized medicine
World Journal of Gastroenterology · 2014 · 398 citations
References
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
British Journal of Cancer · 2007 · 733 citations
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
Annals of Oncology · 2007 · 824 citations
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2008 · 3,144 citations
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
The Lancet Oncology · 2010 · 2,133 citations
<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Cancer Research · 2006 · 2,215 citations
Nonparametric Estimation from Incomplete Observations
Journal of the American Statistical Association · 1958 · 38,793 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.